Alira Health

Alira Health

Market Access: Pharma

Pricing and Reimbursement Strategy

Solutions designed to meet your business goals

Alira Health provides a range of pricing and reimbursement strategies and solutions to deliver commercial success. When you partner with Alira Health you’ll have access to our full spectrum of services, including:
  • Pricing and reimbursement (P&R) landscape assessments
  • Market access strategy development
  • Pricing and reimbursement strategies and value reports
  • Design and facilitation of pricing and reimbursement workshops, complete with cross-functional and international teams
  • Pricing risk assessments

Why choose Alira Health?

As your partner, we’ll work closely with you to uncover opportunities across the pharma industry, accelerate innovation, and deliver tomorrow’s standard of care. You’ll benefit from our:

  • Access to a diverse

    integrated team with deep industry expertise

  • Close collaboration

    with our regulatory and clinical

  • Specific, local insights

    as part of your larger, global strategy—a benefit of having market access teams in both the EU and U.S.

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Jean-François Ricci
Jean-François Ricci
Executive Vice President, Global Market Access
Our strong client partnerships allow us to deliver in-depth, customized strategies and access solutions—all designed to maximize product value across its full lifecycle.

Related News

Events July 18, 2024
UXN Health 2024
Look for patient engagement expert Eduardo Perez onsite in Aarhus to connect on topics like integrating patient voices in solution design.
Co-Design MedTech Patient Engagement Pharma
Articles July 4, 2024
Navigating Market Access for Rare Diseases: The Potential of Real-World Evidence
Our experts answer common questions about the strategic need for real-world evidence to drive market access for rare diseases.
Market Access Rare Disease Real-World Evidence (RWE)
Case Studies June 27, 2024
A Multinational Pharma Targeting Myasthenia Gravis Garners Payer Advice on Market Access
Our client sought to incorporate early payer advice on the MG clinical trial design, identify evidence gaps, and provide insights on the overall development program for the asset.
Market Access Myasthenia Gravis (MG) Rare Disease
Case Studies March 26, 2024
Pharma Company Overcomes Launch Challenges with Patient-Centric Strategy
Our patient engagement team helped this pharma client identify the drivers behind the challenges they faced with their product launch.
Patient Centricity Patient Engagement Pharma
Articles March 18, 2024
WHO Model Lists of Essential Medicines: What You Need to Know 
Our Market Access experts share the importance of the EML for pharma companies and four best practices for a successful application, based on our extensive experience in interactions with the WHO.
Market Access
Case Studies March 12, 2024
Pharma Company Adopts a Patient-Centric Value Proposition for Regulatory and Payer Dossier
A pharma company had a wealth of patient data on a product in development and they wanted to create a long-term strategy that would create a continuity of patient engagement across(...)
Patient Centricity Patient Engagement Pharma
Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.